



HAL
open science

Sex- and species-associated differences in complement-mediated immunity in humans and rhesus macaques

Natasha S Kelkar, Benjamin S Goldberg, Jérémy Dufloo, Timothée Bruel, Olivier Schwartz, Ann J Hessel, Margaret E Ackerman

► **To cite this version:**

Natasha S Kelkar, Benjamin S Goldberg, Jérémy Dufloo, Timothée Bruel, Olivier Schwartz, et al.. Sex- and species-associated differences in complement-mediated immunity in humans and rhesus macaques. *mBio*, 2024, 15 (3), pp.e0028224. 10.1128/mbio.00282-24 . pasteur-04767329

HAL Id: pasteur-04767329

<https://pasteur.hal.science/pasteur-04767329v1>

Submitted on 5 Nov 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Sex- and species-associated differences in complement-mediated immunity in humans and rhesus macaques

Natasha S. Kelkar,¹ Benjamin S. Goldberg,² Jérémy Dufloo,³ Timothée Bruel,^{3,4} Olivier Schwartz,^{3,4} Ann J. Hessel,⁵ Margaret E. Ackerman^{1,2}

AUTHOR AFFILIATIONS See affiliation list on p. 19.

ABSTRACT The complement system can be viewed as a “moderator” of innate immunity, “instructor” of humoral immunity, and “regulator” of adaptive immunity. While sex is known to affect humoral and cellular immune systems, its impact on complement in humans and rhesus macaques, a commonly used non-human primate model system, has not been well studied. To address this knowledge gap, we analyzed serum samples from 90 humans and 72 rhesus macaques for the abundance and activity of the complement system components. While sequences of cascade proteins were highly conserved, dramatically different levels were observed between species. Whereas the low levels detected in rhesus samples raised questions about the suitability of the test for use with macaque samples, differences in levels of complement proteins were observed in male and female humans. Levels of total and antibody-dependent deposition of C1q and C3b on a glycosylated antigen differed between humans and rhesus, suggesting differential recognition of glycans and balance between classical and alternative activation pathways. Functional differences in complement-mediated lysis of antibody-sensitized cells were observed in multiple assays and showed that human females frequently exhibited higher lytic activity than human males or rhesus macaques, which typically did not exhibit such sex-associated differences. Other differences between species and sexes were observed in more narrow contexts—for only certain antibodies, antigens, or assays. Collectively, these results expand knowledge of sex-associated differences in the complement system in humans, identifying differences absent from rhesus macaques.

IMPORTANCE The complement system is a critical part of host defense to many bacterial, fungal, and viral infections. In parallel, rich epidemiological, clinical, and biomedical research evidence demonstrates that sex is an important biological variable in immunity, and many sex-specific differences in immune system are intimately tied with disease outcomes. This study focuses on the intersection of these two factors to define the impact of sex on complement pathway components and activities. This work expands our knowledge of sex-associated differences in the complement system in humans and also identifies the differences that appear to be absent in rhesus macaques, a popular non-human primate model. Whereas differences between species suggest potential limitations in the ability of macaque model to recapitulate human biology, knowledge of sex-based differences in humans has the potential to inform clinical research and practice.

KEYWORDS antibody effector function, complement, cytolysis, rhesus macaques, nonhuman primate

Biological factors both influence the composition and development of the immune system and its responses to pathogens. It is believed that sex-based differences in

Editor Sabra Klein, Johns Hopkins University, Baltimore, Maryland, USA

Address correspondence to Margaret E. Ackerman, margaret.e.ackerman@dartmouth.edu.

The authors declare no conflict of interest.

See the funding table on p. 19.

Received 31 January 2024

Accepted 5 February 2024

Published 22 February 2024

Copyright © 2024 Kelkar et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

immunity are a consequence of genetic differences attributable to the X chromosome, which encodes immunity genes such as Toll-like receptors, cytokine receptors, genes involved in B cell and T cell activity, and transcriptional and regulatory factors (1). Conversely, the Y chromosome, which is exclusively present in males, encodes for genes involved in inflammatory pathways (2). Hormones further contribute to the difference between male and female immune responses (1).

Sex-associated differences in immune responses evolved in diverse species ranging from insects, lizards, birds, and mammals (3). For example, many genes that encode for innate immune signaling proteins in *Drosophila melanogaster* are found on the X chromosome and show sex-specific induction in bacterial and fungal infection (4, 5). In humans, sex-based differences have been demonstrated in infectious diseases like COVID-19 (6–10), HIV (11), influenza (12), and mumps (13). Both flow cytometric and single-cell transcriptomics experiments have revealed that females have a lower percentage of natural killer cells in peripheral blood as compared to males (14, 15). Studies also demonstrate that females have higher phagocytic activity of macrophages and neutrophils (16) and higher CD4/CD8 ratios as compared to age-matched males (15, 17–21) and more efficient antigen presentation than in males (22). Sex-based differences in vaccine-induced humoral immunity have been seen in children and adults. Adult females are generally known to develop higher antibody titers due to enhanced immune activation than their male counterparts (23, 24), a difference that has suggested the value of different vaccine dose protocols for males and females (23). Females also more frequently elicit immune responses against self and are hence more likely to develop autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis than males (25, 26). The varied mechanisms at play in driving these associations are not yet fully described, but differences in endocrine-immune interactions between females and males are known to contribute to sex-based differences in immune responses (27, 28).

Sex-based differences in the immune system have also been reported in rhesus macaques, a popular model system used to study immune responses given their genetic similarity to humans. For example, one rhesus macaque study reported a lower infection rate among unvaccinated females as compared to males following a challenge with simian-human immunodeficiency virus and vaccine efficacy that was only observed among male animals (29, 30). A study designed to determine if complement lysis of simian immunodeficiency virus (SIV) or SIV-infected cells represents a correlate of protection against SIV infection demonstrated that induction of antibodies capable of directing complement lysis post vaccination differed between males and females (31). The study demonstrated that antibody-dependent SIV lysis correlated with reduced risk of infection in vaccinated males, particularly in gp140 immunized males, but not in females. Vaccinated males in the study had higher Env-specific IgM titers than vaccinated females. A previous SIV vaccine efficacy study that focused on exploring immunogenicity and protective efficacy of monomeric SIV gp120 with oligomeric SIV gp140 in rhesus macaques demonstrated that females exhibited delayed SIV acquisition as compared to males, which is associated with enhanced mucosal B cell responses at the site of virus exposure (32). Subsequent study demonstrated that several immune parameters developed differently in vaccinated males and females, including T_{FH} , Env-specific antibody levels, and B_{reg} frequencies (33, 34). Such sex-associated differences may be widespread, as a study in Chinese rhesus macaques showed higher levels of leukocyte sub-populations in females (35).

In contrast to humoral and cell-based immunity, sex-based differences in complement pathway-mediated immunity are less studied, although some differences have been reported (36). The complement system is an innate immune surveillance system comprised of both soluble and membrane-bound proteins. The system can be activated by three distinct initiation events—classical, alternative, and lectin pathways, each leading to a common terminal pathway. Recognition of pathogen-associated molecular patterns or binding of complement protein C1q to the Fc portion of IgG or IgM antibodies complexed with antigen can induce the activation of classical complement

pathway. The triggering force behind activation of lectin pathway is recognition of pathogen-associated carbohydrates by mannose-binding lectin (MBL), followed by induction of the complement cleavage cascade through activation of MBL-associated serine proteases. The alternative complement pathway is activated when spontaneous hydrolysis of a thioester bond in complement protein C3 reaches a critical threshold (37, 38). All three pathways give rise to formation of C3 convertase (C4b2b in classical and lectin pathways, C3bBb in alternative pathway), which catalyzes proteolytic cleavage of complement protein C3 into C3a and C3b. C3b binds to C3 convertase to form C5 convertase which cleaves protein C5 into C5a and C5b. C5b recruits complement proteins C6, C7, C8, and C9. Polymerization of C9 with the membrane leads to formation of the membrane attack complex which forms pores that disrupt membrane integrity and lead to lysis (39). Many steps in the pathway are held in check by regulatory molecules, so that activity of complement proteins is preferentially confined to appropriate pathogenic surfaces, minimizing bystander tissue damage.

Apart from the role of the complement pathway in innate immune responses which include opsonization, lysis, and generation of inflammatory responses through soluble mediators, the pathway also has a role in adaptive immunity. Studies have demonstrated that depletion of C3 impairs humoral immune responses (40). Acting as a functional bridge between innate and adaptive immune responses, the complement system can enhance B cell immunity through complement receptor 1 (CR1) and CR2 expressed on B lymphocytes and follicular dendritic cells (41). Complement effectors are engaged with humoral immunity at multiple stages of B cell differentiation (42, 43), motivating consideration of its role as an "instructor to humoral immune response" (41). Antigen and immune complexes can be transported to follicular dendritic cells and to germinal centers in a complement-dependent manner (44, 45).

Although the precise mechanism(s) by which complement regulates T cell immunity are not known, studies have demonstrated links between complement activation and enhanced T cell responses. Antagonism of complement receptor C5aR results in fewer antigen-specific CD8 T cells following influenza A infection (46), and this same receptor mediates a synergistic effect with Toll-like receptor 4 in eliciting a stronger inflammatory response (47). Crosslinking of complement inhibitory proteins, namely, membrane cofactor protein, decay activating factor (DAF), and complement receptor CR1, can result in direct modulation antigen-presenting cells or T cell function (41). Crosslinking of CR1 inhibits proliferation and reduces IL-2 production (48). DAF has multifaceted role in T cell biology which includes suppression of T cell responses as well as proliferation of CD4 T cells (49).

Given the importance of the complement system to many aspects of immunobiology, we aimed to explore the extent of similarity and differences in complement pathway-mediated immunity between males and females and in humans and rhesus macaques. Better knowledge of sex- and species-associated levels and activities of complement cascade components have the potential to not only inform study design and interpretation but also provide insights that might contribute to advances in clinical care.

RESULTS

Complement proteins are highly conserved in humans and rhesus

The complement system is comprised of a series of activating and suppressing proteins, expressed in soluble form as well as on cellular membranes that interact and catalyze transformations that can either negatively regulate or result in loss of membrane integrity (Fig. 1A). We wished to explore the conservation of human and rhesus proteins at the level of primary structure and obtained the sequences of complement proteins from humans and rhesus from the UniProt database (50) (Table 1). Because complement component C1q subunit A, complement component 7, factor H, and factor I proteins of rhesus were not annotated, sequences for these proteins were obtained by applying BLAST (Basic Local Alignment Search Tool) algorithm (51) using human sequences as a query on the *Macaca mulatta* proteome. The alignment score as calculated by the




FIG 1 Study design. (A) Complement pathway with complement proteins studied quantitatively in this work are highlighted in blue, and complement proteins studied quantitatively and functionally are highlighted in yellow. (B) The cohort used for the study comprised of 90 human serum samples (45 females and 45 males) and 72 rhesus serum samples (40 females and 32 males). A median split based on age was performed to categorize human and rhesus samples into two groups. Illustration created with BioRender.

TABLE 1 Extent of homology between human and rhesus complement cascade proteins studied^a

Protein	Human protein UniProt ID (length in aa)	Rhesus protein UniProt ID (length in aa)	Alignment score (%)
Complement component C1q-subunit A	P02745 (245)	A0A5F8AD02 (244) ^b	90.17
Complement component C1q-subunit B	P02746 (253)	G7MHG1 (253)	95.26
Complement component C1q-subunit C	P02747 (245)	F7HEL0 (245)	96.33
Complement component C1r	P00736 (705)	H9FZ50 (705)	96.31
Complement component C1s	P09871 (688)	H9FZ52 (688)	94.04
Complement component C2	P06681 (752)	F6YK65 (752)	97.87
Complement component C3	P01024 (1,663)	F7EV32 (1,663)	95.01
Complement component C4b	POCOL5 (1,744)	H9YW54 (1,744)	96.16
Complement component C5	P01031 (1,676)	F7GHV1 (1,676)	95.94
Complement component C6	P13671 (934)	G7MV56 (934)	95.93
Complement component C7	P10643 (843)	A0A5F7ZV76 (843) ^b	96.24
Complement component C8	P07357 (584)	F6U5Q9 (584)	94.69
Complement component C9	P02748 (559)	F7GRY2 (561)	91.23
Factor B	P00751 (764)	F6YJY7 (763)	94.63
Factor D	P00746 (253)	F6YBP7 (260)	94.47
Factor H	P08603 (1231)	A0A5F7ZT34 (1,232) ^b	88.14
Factor I	P05156 (583)	A0A1D5QTK1 (570) ^b	90
Mannose-binding lectin	P11226 (248)	A0A1D5R122 (225)	89.52

^aPairwise global alignment of human and rhesus complement proteins using ClustalW. Alignment score is defined as percent identity.

^bRepresents proteins identified by performing BLAST analysis of human complement protein on the rhesus proteome.

ClustalW algorithm (52) revealed that complement proteins in humans and rhesus are highly conserved. Among the complement proteins considered for sequence-based conservation analysis, the lowest sequence alignment score was observed for factor H (88.14%), and the highest was observed for C2 (97.87%). Notably, the globular head of C1q subunit B, which interacts with IgG, is well conserved between species, including the putative contact regions (Fig. S1) (53–55). However, none of the complement proteins that were considered in this analysis are identical in humans and rhesus.

Complement protein abundance in humans and rhesus

In humans, the levels of many of these proteins can be assessed in multiplexed assays; however, the suitability of these assays for use with non-human primate (NHP) samples has not been reported. Here, the levels of complement proteins were assessed in serum samples from all 90 human and a subset of the total 72 rhesus samples from a relatively even mix of male and female donors (Fig. 1B; Table S1). Higher median fluorescent signal intensity (MFI) magnitudes for all complement system analytes were observed in human serum samples as compared to rhesus (Fig. 2A; Data File S1). While the high degree of amino acid sequence conservation between the human and rhesus complement proteins suggests that it is reasonable to expect the anti-human complement reagents in this experiment to cross-react with rhesus complement proteins, the fact that many analytes exhibited essentially undetectable signal indicates otherwise. Collectively, these results call into question the suitability of these reagents to define levels of cascade components among NHP.

In humans, complement protein C1q and C2 were more abundant in females as compared to males (Fig. 2B and C). In contrast to observations in humans, sex bias in serum complement protein levels was not seen in rhesus (Fig. S2), although the limited signal observed for most analytes may have reduced or eliminated the ability to detect differences.




FIG 2 Quantification of complement proteins in human and rhesus serum. (A) Median fluorescent intensities (MFIs) observed in the standard curve for each human complement pathway protein (left) and for human (green) and rhesus (pink) sera samples (right) from female (solid) and male (hollow) donors. Dashed line indicates buffer-only control. Bar indicates median. (B) Volcano plot depicting the magnitude (fold change) and statistical significance (Welch’s *t*-test) of differences in levels of complement proteins in human males and females. Dotted horizontal line indicates unadjusted *P* value of 0.05. (C) Box plots comparing the levels of select complement proteins in human females and males. Statistical significance defined by Welch’s *t*-test (**P* < 0.05; ns, *P* > 0.05). Dashed line indicates buffer-only control. Bar indicates median.

Human serum shows higher antibody-dependent complement deposition than rhesus serum

Antibody-dependent deposition of complement proteins C1q and C3b was tested with two human monoclonal antibodies [10-1074 (56) and VRC01 (57)] specific for different epitopes on the HIV envelope (Env) glycoprotein and pooled polyclonal serum IgGs from people living with HIV (HIVIG) using individual human and rhesus serum samples as a source of complement at two different concentrations. This assay was multiplexed across different sequence variants ($n = 11$; Table S2) of the Env glycoprotein (Fig. 3A). C1q and C3b deposition on these Env glycoproteins was also evaluated in the absence of antibody. In general, 10-1074 elicited higher deposition of complement proteins as compared to VRC01 (Fig. 3B), consistent with generally superior opsonization (Fig. S3), which was not standardized or normalized.

In the absence of antibody, rhesus serum showed higher C3b deposition as compared to human serum (Fig. 3B), confounding analysis of differences in antibody-dependent C3b deposition. Hence, interspecies comparisons of antibody-dependent C3b deposition were not performed. Such differences were not seen in case of C1q deposition in the absence of antibody. Overall, human serum showed higher antibody-dependent deposition of complement protein C1q as compared to rhesus (Fig. 3C; Data File S2). Whereas C1q deposition among females was not distinct between species, elevated responses were observed for C1q in human males as compared to rhesus males (Fig. 3C).

Sex-based differences in complement deposition observed in humans

We then studied sex-based differences in humans and rhesus for antibody-dependent deposition of complement proteins C1q and C3b. Despite exhibiting lower levels of C1q in serum (Fig. 1B and C), human males showed higher deposition of complement protein C1q as opposed to human females in this assay (Fig. 3D, top left). This degree of sex-associated difference was not observed among rhesus (Fig. 3D, top right). For complement protein C3b, human males showed higher deposition as compared to human females for both antibody-independent and antibody-dependent measures (Fig. 3D, bottom left). In contrast, for a few antigens, rhesus females showed higher deposition of both C1q and C3b as compared to rhesus males (Fig. 3D, bottom right; Data File S2 and S3), although again, antibody-independent C3b deposition was high in rhesus.

Sex- and species-based differences in antibody-dependent complement-mediated lysis (ADCML)

Three different functional assays were performed to evaluate the ADCML activity of human and rhesus serum. In the first assay, lysis of sheep red blood cells (RBCs) was performed to evaluate differences in ADCML elicited by human and rhesus serum by the classical complement pathway (58). Hemolysin (rabbit Ig) was used as the source of anti-sheep erythrocyte antibody, and the amount of hemoglobin released from sheep RBC post addition of serum samples was measured (Fig. 4A). Because the surface of sheep RBC is rich in sialic acid, factor H is able to bind to it, blocking the alternative pathway of complement activation (59). Human serum samples ($n = 90$) demonstrated higher hemolysis of sensitized sheep RBC as compared to rhesus serum samples ($n = 72$) (Fig. 4B). In contrast, differences were not observed between either non-antibody-mediated hemolysis or heat-inactivated serum, which was assessed in just a few samples as a negative control, between species (Fig. 4B).

The differences in hemolytic activity between species could be attributed to sex-specific differences. Whereas serum from human females ($n = 45$) elicited greater hemolysis of sensitized RBC as compared to serum from human males ($n = 45$), sex-associated differences were not observed in rhesus macaques (32 males, 40 females) (Fig. 4C). Serum from human females elicited higher hemolysis as compared to serum from rhesus females, while differences between human and rhesus males were not observed (Fig. 4C).




FIG 3 Antibody-dependent C1q and C3b deposition. (A) Schematic depicting complement deposition multiplex assay in which VRC01 or 10-1074 mAbs, or polyclonal serum IgG from people living with HIV (HIVIG) were used to opsonize fluorescently coded beads conjugated with various HIV envelope glycoproteins and assess C1q and C3b deposition following incubation with human or rhesus donor serum. Illustration created with BioRender. (B) Box plot of total C1q (top) and C3b (bottom) detected on an envelope glycoprotein (clade B SF162 gp140) using antibodies VRC01, 10-1074, HIVIG, and no antibody control for human (green) and rhesus (pink) serum. Statistical significance defined by ordinary one-way analysis of variance (**** $P \leq 0.0001$; ns, $P > 0.05$). (C–D) Volcano plots of significance (Welch’s t -test) and mean fold change of antibody-dependent deposition for C1q between species across all (left), female (center), or male (right) serum samples (C) and of C1q (top) and C3b (bottom) in humans (left) and rhesus (right) for complement protein between sexes (D). Symbol shapes indicate serum concentration and antibody used, and color indicates the antigen. Dotted horizontal line indicates unadjusted $P = 0.05$.




FIG 4 Hemolytic activity of human and rhesus serum. (A) Schematic depiction of assay used to evaluate the lytic activity of human and rhesus serum against sensitized (S) sheep red blood cells (RBCs). Illustration created with BioRender. (B) Hemolysis of sheep RBCs mediated by human (green) or rhesus (pink) serum. Non-sensitized (NS) sheep RBCs and heat-inactivated (HI) serum were used as controls. (C) Sex-associated differences in hemolysis mediated by human or rhesus serum using sensitized (S) sheep RBCs. Statistical significance defined by ordinary one-way analysis of variance (**** $P < 0.0001$; ns, $P > 0.05$). Bar indicates median.

Sex- and species-based differences in ADCML with human and simianized antibodies

Next, we assessed ADCML mediated by the anti-CD20 antibody rituximab (Rtx) and its simianized equivalent (Rh Rtx), in which Rtx complementarity determining regions were grafted onto rhesus kappa light chain and IgG1 heavy chains. Antibody was added to CD20+ Ramos cells, followed by addition of serum as a source of complement. The activity of proteases released by lysed Ramos cells was measured using




FIG 5 Rituximab-mediated lysis activity of human and rhesus serum. (A) Schematic depiction of assay used to evaluate the lytic activity of human and rhesus serum against rituximab-treated Ramos B cells. Illustration created with BioRender. (B) Lysis of Ramos cells using human (green) or rhesus (pink) serum in the presence and absence of human (Rtx, purple) and rhesusized (Rh. Rtx, fuschia) anti-CD20 antibody. (C) Antibody-dependent lysis of Ramos cells. (D) Sex-associated differences in antibody-dependent lysis. Statistical significance defined by ordinary one-way analysis of variance (**** $P < 0.0001$; **** $P < 0.001$; ** $P < 0.01$; * $P \leq 0.05$; ns, $P > 0.05$). Bar indicates median.

a luminescence-based assay (Fig. 5A). While differences death mediated by serum between species were not observed, the Rh Rtx exhibited greater activity than Rtx, indicating greater activity of the rhesus than human IgG1 backbone, although a difference in post-translational modifications cannot be ruled out (Fig. 5B). Consistent with the greater deposition of complement cascade factors observed in the bead assay, lysis in the absence of antibody was higher in rhesus as compared to human serum (Fig. 5B). When the relative magnitudes of antibody-elicited cell death were compared to those observed in the absence of antibody on a per subject basis, human serum samples elicited higher ADCML as compared to rhesus serum for both antibodies (Fig. 5C), as did serum samples from human females as compared to either human males or rhesus females (Fig. 5D). Sex-associated differences in lysis were not observed for either antibody in rhesus macaques.

Species-based differences in ADCML with Fc-engineered antibodies

Lastly, ADCML of Raji cells expressing varying surface density of HIV-1_{YU-2b} Env antigen was performed using a limited number of human (*n* = 3) and rhesus (*n* = 3) serum samples for multiple Fc domain-engineered monoclonal antibodies (mAb) (Fig. 6A; Fig. S4). The broadly neutralizing antibodies 10-1074 (56), VRC01 (57), and 10e8v4 (60), which are known to exhibit complement-mediated lytic activity (61–63), were tested. Among the mutations in the antibodies, LALA and KA substitutions are known to reduce complement activity, and EFTAE and EG have been reported to enhance complement activity (64–68). Among the antibodies, 10-1074 exhibited the greatest lytic activity, VRC01 was intermediate, and 10e8v4 exhibited the lowest activity for both human and rhesus serum and for both high and low Env expression levels (Fig. 6B). Rhesus




FIG 6 Lytic activity of Fc-engineered antibodies. (A) Schematic depiction of assay used to evaluate HIV-1 envelope-specific lysis mediated by engineered antibodies. Illustration created with BioRender. (B) ADCML of Raji cells expressing high (top) and low (bottom) levels of HIV envelope glycoprotein using antibodies 10-1074 (left), VRC01 (center), and 10e8v4 (right) with and without Fc domain mutations designed to increase (EFTAE, EG) or decrease (KA, LALA) complement activation in serum from human (green, *n* = 3) and rhesus (pink, *n* = 3). Unmodified IgG (WT, wild type) activity is indicated in gray region in each subpanel. Percentage of cell lysis was calculated with respect to a no antibody control. Bar indicates median.

serum often but not always exhibited greater activity than human serum. The extent to which KA and LALA mutations reduced activity depended on mAb, antigen density, and complement source (Fig. 6B, activity relative to unmodified antibody shown in Fig. S5). For example, these mutations greatly reduced the activity of 10e8v4 for both cell targets and both species, but only marginally reduced the activity of 10-1074 in the context of high Env expression for most complement serum donor samples. For VRC01, greater reductions were typically observed for human than rhesus serum samples. EFTAE and EG mutations, which improve affinity for C1q or increase IgG hexamerization propensity, respectively, reliably exhibited improved lytic activity across mAbs, varying Env density, and for both rhesus and human serum. The extent of improvement was typically greater for mAbs and antigen density conditions for which high activity of the unmodified mAb was not observed. Although the overall sample size of human and rhesus macaque serum used to test the effect of Fc-engineered antibodies on ADCML was low, consistent with other studies (64, 69, 70), these data demonstrate the suitability of Fc engineering mutations designed to influence activity in humans to extend to rhesus, albeit with perhaps slightly reduced degree of modulation, while at the same time reinforcing the high degree of context dependence on complement activation.

Sex- and species-based differences in complement-aided antibody-dependent phagocytosis (C'ADCP) with human and rhesus serum

Antibody-mediated phagocytosis can be triggered by either or both Fc and complement receptors. THP-1 cells (monocytes) express the CR3 receptor, which can recognize iC3b and drive internalization of antigenic particles (71–73). We assessed phagocytosis elicited in the presence of complement proteins by VRC01, 10-1074, and HIVIG (Fig. 7A; Fig. S6). Human serum samples ($n = 90$) demonstrated higher phagocytotic activity as compared to rhesus serum sample ($n = 56$) for both 10-1074 and HIVIG. No difference in phagocytotic activity was seen in case of VRC01 or media alone (Fig. 7B). Consistent with earlier observations of reduced deposition of C1q and C3b, VRC01 showed lower C'ADCP as




FIG 7 Complement-aided antibody-dependent phagocytotic activity of human and rhesus serum. (A) Schematic depiction of assay used to evaluate the complement-aided antibody-dependent phagocytosis (C'ADCP) by human and rhesus serum against antibodies VRC01, 10-1074, and HIVIG. Illustration created with BioRender. (B) Box plot of phagocytosis scores of HIV-1 envelope glycoprotein (clade B, YU2 gp140 trimer) beads using human (green) or rhesus (pink) serum in the presence and absence of VRC01 (mauve), 10-1074 (pink), HIVIG (brown), or media alone. (C) Sex-associated differences in C'ADCP. Statistical significance defined by ordinary one-way analysis of variance (**** $P < 0.0001$; *** $P < 0.001$; ** $P < 0.01$; * $P \leq 0.05$; ns, $P > 0.05$). Bar indicates median.

	Human vs Rhesus	Human Female vs Human Male	Rhesus Female vs Rhesus Male	Human Female vs Rhesus Female	Human Male vs Rhesus Male
Levels of complement cascade proteins	NA	Human Female ↑ C1q, C2	NA	NA	NA
C1q deposition on a HIV-1 envelope protein in an antibody-independent manner	Similar	Similar	Similar	Similar	Similar
C1q deposition on a HIV-1 envelope protein using human anti-HIV envelope antibodies	Human ↑	Human Male ↑	Similar	Similar	Human Male ↑
C3b deposition on a HIV-1 envelope protein in an antibody-independent manner	Rhesus ↑	Human Male ↑	Similar	NA	NA
Hemolysis of sheep RBC in absence of hemolysin	Similar	NA	NA	NA	NA
Sheep RBC hemolysis in presence of hemolysin (rabbit Ig)	Human ↑	Human Female ↑	Similar	Human Female ↑	Similar
Antibody-independent lysis of Ramos B cells	Rhesus ↑	NA	NA	NA	NA
Fold change of (human IgG) Rtx-mediated lysis of Ramos B cells wrt antibody-independent lysis	Human ↑	Human Female ↑	Similar	Human Female ↑	Similar
Fold change of (rhesus IgG) Rh. Rtx-mediated lysis of Ramos B cells wrt antibody-independent lysis	Human ↑	Human Female ↑	Similar	Human Female ↑	Similar
C'ADCP of beads coated with HIV-1 envelope in antibody-independent manner	Similar	Similar	Similar	Similar	Similar
C'ADCP of beads coated with HIV-1 envelope using human anti-HIV mAb VRC01	Similar	Similar	Similar	Similar	Similar
C'ADCP of beads coated with HIV-1 envelope using human anti-HIV mAb 10-1074 and HIVIG	Human ↑	Similar	Rhesus Male ↑	Human Female ↑	Rhesus Male ↑
Effect of enhancing mutations EFTA E and EG in human IgG	Human ↑	NA	NA	NA	NA
Effect of reducing mutations KA and LALA in human IgG	Human ↑	NA	NA	NA	NA

FIG 8 Summary of sex- and species-associated differences in complement-mediated immunity observed in this study. Summary of various sex- and species-associated comparisons (row headings) across experiments (columns). NA indicates when groups were not compared.

compared to 10-1074 or HIVIG, and 10-1074 demonstrated higher C'ADCP as compared to HIVIG (Fig. 7B).

The differences in phagocytic activity between species could be attributed to sex-specific differences. Serum from human females elicited higher phagocytotic activity than rhesus females for 10-1074 and HIVIG (Fig. 7C). No such interspecies difference was observed in males. Whereas no difference in C'ADCP was observed among human females and human males, serum from rhesus males elicited higher C'ADCP activity as compared to serum from rhesus females for 10-1074 and HIVIG (Fig. 7C).

Collectively, serum from humans often but not always exhibited greater complement-mediated lysis activity than from rhesus, and these species-level differences could generally be attributed to the greater lytic activity observed in human females (Fig. 8).

DISCUSSION

Sex-based differences in immune responses are known to impact the severity, pathology, and prognosis of diseases. However, there is limited understanding about sex-associated differences due to complement-mediated immunity in humans and rhesus macaques, a non-human primate model organism used to study immune responses and model disease. By measuring the levels of various complement cascade proteins in serum as well as a battery of complement activities in various functional assays, the current study sought to compare complement pathway-mediated immunity between the sexes in humans and rhesus macaques. The sex-associated differences as well as the balance between classical and alternative pathway-mediated complement activation among species differed, suggesting potential limitations of the macaque model to fully mimic human biology.

The resulting data suggest sex-associated differences in complement pathway among humans as well as rhesus macaques. Our data demonstrated higher abundance of basal complement proteins complement protein C1q and C2 in human females as compared

to human males. While not statistically significant, levels of MBL and C3b were lower among females in this cohort, an observation supported by a better powered prior study (74), which also reported lower levels of factor D in females, an observation that was not reproduced in the samples profiled here. Supporting these observations, analysis of B cells from individuals 20–30 years of age demonstrated overrepresentation of differentially expressed genes from the classical complement pathway in females as compared to males (14), although hepatocytes are thought to be the main source of complement proteins in serum.

In humans, activation of early complement pathway components was higher in males, while antibody-mediated cell lysis was higher in females. Perhaps consistent with these observations, studies in mice have demonstrated that females were dependent on MBL-mediated initiation of complement pathway, whereas males employed C1q as well as MBL to initiate the complement cascade (75). Such sex-associated differences may be due to interaction of sex hormones and the complement pathway. Indeed, the promoter of the complement protein C3 gene is responsive to stimulation by estrogen in transcriptional assays in mammalian cells (76). High levels of estrogen in females have also been shown to influence recruitment of factor H, which in turn acts as inhibitor of alternative complement pathway (77).

Some striking differences were also observed between species. Higher antibody-independent deposition of complement protein C3b was observed in rhesus as compared to humans. Higher C3b deposition could be due to direct activation of complement protein C3 via antigen glycans through the lectin or alternative pathway. Antibody-independent activation of complement is an important innate immune response giving rise to cell lysis, and these results suggest a differing balance between the classical and alternative pathway of complement deposition in the two species. Such host-associated differences have precedence. For example, a prior study demonstrated that antibody-mediated lysis of *Staphylococcus aureus* in complement-dependent and complement-independent manners in BALB/cJ and C57BL/6J mice, respectively, highlighting the role of even strain-specific factors to contribute to the activity of complement-dependent pathways and antibody mechanisms of action (78).

Although the present study demonstrates sex- and species-based differences in complement pathway-mediated immunity in humans and rhesus macaques, it has a number of limitations. The complement pathway consists of about 50 proteins, and levels of all the proteins were not measured. Although the cohorts used include a variety of subjects in different age ranges, human serum samples from individuals younger than 19 years of age or older than 77 years of age were not evaluated. Similarly, rhesus younger than 2.3 years of age or older than 21.2 years of age were not profiled. As a result, the study failed to capture well-powered number human and rhesus serum samples across age ranges in which hormonal regulation of immunity would be most likely to be observed. Hence, age-based comparisons were not made. Multiplex assays developed to quantify human complement proteins were used for detection of rhesus proteins, which despite a high degree of sequence similarity, did not show detectable levels of many analytes. Samples were collected at different sites, and while care was taken to perform sample collection and handling consistently, uniformity could not be guaranteed. Genetic and environmental exposure history of human and rhesus macaque subjects was not available; hence, differences in genetic polymorphisms could not be studied. While some sex-associated differences were observed across assays, others were context dependent, consistent with the sensitivity of complement activation to many factors. While the current study highlights possible interaction of sex hormones and complement pathway proteins, information on hormone therapy status or hormone levels of the subjects was not available; hence, correlative relationships between sex hormones and complement protein levels or activity could not be determined.

Lastly, despite a high degree of sequence conservation, the binding affinities of rhesus and human C1q for IgG may differ. Such differences could contribute to the differences observed between species and may be relevant to extrapolation of results

from NHP experiments to the clinic. However, the residues in the globular head region of human C1q subunit B expected to bind to IgG identified by molecular modeling and mutational experiments are conserved in human and rhesus C1qB, making it reasonable to expect cross-reactivity between the human IgG and rhesus C1q, and vice versa, consistent with observations between IgG and FcγR between species (79–83). Similarly, the rabbit-origin hemolysin used may likewise interact differentially with human and rhesus complement proteins. All assay choices present some compromises. Here, rather than species matching, we held antibody constant in each experiment in order to isolate differences associated with the complement cascade from those associated with immunoglobulins, which do differ in both structure and function between species, across IgG subclasses, and among allotypes (79, 84–86).

Most of the deficiencies in complement components are inherited in an autosomal codominant pattern. Acquired deficiency defects of complement may result from increased consumption, decreased synthesis, or increased catabolism of complement proteins. Individuals with complement component deficiency often present with pyogenic infections by organisms like *Streptococcus pneumoniae*, *Haemophilus influenzae* type B, *Neisseria gonorrhoeae*, and *N. meningitidis*, whereas autoimmune diseases often result in secondary complement deficiencies (87). Plasma infusions have been occasionally used as source for deficient complement components (88). Sex bias in complement protein levels suggests that sex matching of donor plasma may be worth considering.

As mentioned earlier, the level of complement proteins in plasma is determined by the balance of synthesis and consumption. The C1 inhibitor (C1-Inh) protein provides inherent stability to the complement pathway by inactivating C1r and C1a, leading to liberation of free C1q. Here, we observe higher basal levels of C1q in human females as compared to human males but a higher level of antibody-dependent C1q deposition human males. These results might indicate sex-associated differences in level of C1-Inh. C1-Inh deficiency leads to a rare disorder, hereditary angioedema, which demonstrates a greater disease burden in women as compared with men (89–91). Studies demonstrate that disease severity is exacerbated by increased exposure to estrogen (92), again highlighting the possible interaction of sex hormones and complement pathway proteins. Similarly, a study in participants suffering from late-stage knee osteoarthritis demonstrated that complement pathway activation may play a role in synovial vascular pathology mechanisms in males than in females. It also highlighted that females do not activate terminal complement pathway as effectively as males, regardless of the level of C5 present in synovial fluid (93).

Although the complement pathway has many protective functions in immunity, imperfect regulation of complement proteins causes tissue damage in diseases like rheumatoid arthritis, age-related macular degeneration, multiple sclerosis, and ischemia reperfusion injury, among others (94, 95). Failure to model or consider the impact of sex-associated differences has the potential to impact studies of these disease states and may contribute to challenges in the “bench to bedside” extrapolation of these inhibitors to clinical applications (96). As an example, complement inhibitors have been tested for treatment of traumatic brain injury (97–100). While multiple factors are certainly at play, most ischemia reperfusion studies use male mice, which exhibit differential terminal complement pathway activity from female mice in common strains (101). Consistent with these differences, a recent study demonstrated that the complement initiation response to ischemia reperfusion injury differed in male and female mice: C1q-deficient male but not female mice were protected from injury, whereas MBL deficiency protected both male and female mice (75), suggesting a difference in the relative contributions of classical and lectin-mediated complement cascades. Similarly, age-related macular degeneration is a chronic degenerative disease of the retina, caused by elevation in complement proteins. A recent study among patients with intermediate age-related macular degeneration demonstrated higher levels of complement factor B and complement factor I in females as compared to males (102).

These and other studies support consideration of sex-based differences in the design and interpretation of preclinical models. To this end, this study highlights sex-based differences in complement pathway-mediated immunity in humans and rhesus macaques. A number of the sex-based differences observed were species specific, suggesting some limitations in the ability of the macaque model to fully recapitulate aspects of human biology that may be relevant to disease. Other differences were highly context dependent, suggesting the continued value of functional evaluation of complement activities across clinical and biological contexts in which it may play a role.

MATERIALS AND METHODS

Cell lines

Ramos and Raji cells were purchased from ATCC and maintained in RPMI-1640 containing 10% fetal bovine serum (FBS) at 37°C with 5% CO₂. Raji cells expressing HIV-1 envelope were generated as described previously (63). The cells were maintained in RPMI-1640 containing 10% FBS and 1 µg/mL puromycin (InvivoGen, ant-pr-1). The THP-1 human monocytic cell line was purchased from ATCC and maintained in RPMI-1640 supplemented with 10% FBS and 55 µM beta-mercaptoethanol at 37°C with 5% CO₂.

Serum sample acquisition

Human serum samples screened for HIV-1, HIV-2, hepatitis B, syphilis, West Nile virus, and hepatitis C were purchased commercially (BioIVT, HUMANSRMMN5, and HUMANSRMFN5). Among the samples, 50% were from females ($n = 45$), and remaining 50% were from males ($n = 45$). Serum samples from Indian-origin rhesus macaques were acquired from Oregon Health and Science University. Among the set of 72 samples, 55.56% ($n = 40$) were from female macaques, and the remaining 44.44% ($n = 32$) were from male macaques. Serum samples were collected by a method that preserves complement functional integrity. Briefly, blood was allowed to clot at 4°C and centrifuged for 10 min at 1,200 × *g*. The serum (top, clear) layer was then collected, aliquoted, and stored at –80°C within 2 hours of blood draw. Serum samples were aliquoted and stored at –80°C to avoid repeated freeze-thaw cycles.

Sequence alignment

Amino acid sequences of complement cascade proteins were obtained from the UniProt database (www.uniprot.org). Rhesus complement component C1q subunit A, complement component 7, factor H, and factor I sequences were not available in the UniProt database and were instead putatively identified by homology to their human homologs by performing a BLAST (<https://www.uniprot.org/blast>) search on the rhesus proteome.

Measuring levels of complement proteins in human and rhesus serum

Multiplex assay panels (Millipore Sigma, HCMP1MAG-19K and HCMP2MAG-19K) were used for detection of complement proteins essentially according to the manufacturer's instructions. Serum samples were diluted 1:200 and 1:40,000 for HCMP1MAG-19K and HCMP2MAG-19K, respectively, using assay buffer as the diluent. The assay was performed by modifying manufacturer's instruction to perform assay in a 384-well plate as published by Tang et al. (103). Plates (Greiner bio-one, 781906) were blocked with 50 µL of phosphate buffered saline (PBS) containing 1% bovine serum albumin (BSA) for 10 min at room temperature with shaking (1,000 rpm). Serum samples were diluted in cold gelatin veronal buffer containing Ca²⁺ and Mg²⁺ (GVB++) (Complement Technology, B100) and were then added to the 384-well plate. As per the manufacturer's instruction, 6 µL of premixed beads conjugated with antibodies specific to complement proteins was added to each well containing the serum samples. The plate was sealed, wrapped with foil, and incubated with agitation at 1,000 rpm on a plate shaker for 2 hours at

room temperature. The plate was washed using a plate washer according to manufacturer's instructions, and 6 μL of provided detection antibody was added. The plate was sealed, covered with foil, and incubated with agitation for 1 hour at room temperature, followed by the addition of 6 μL of streptavidin-phycoerythrin. The plate was again sealed, covered with a foil, and allowed to incubate with agitation at 1,000 rpm on plate shaker for 30 min at room temperature prior to washing and resuspension with 50 μL of sheath fluid (Luminex xMAP Sheath Fluid Plus, 4050021), sealed (Eppendorf, catalog no. 0030127854), and agitated at 1,000 rpm for 5 min. Data were acquired on a Luminex FLEXMAP 3D Instrument System, which detected the beads and measured PE fluorescence in order to calculate the MFI level for each analyte. Heat-inactivated pooled human sera (Sigma-Aldrich, S1764) and rhesus sera were used as negative controls. Heat inactivation was performed by heating serum at 58°C for 30 min. The standards in the kits were used as positive controls.

Antibody-dependent deposition of complement proteins C1q and C3b

Recombinant extracellular domains of HIV envelope proteins (NIH HIV Reagent Program; Table S2) were covalently coupled to Luminex Magplex magnetic microspheres using the two-step carbodiimide chemistry as described previously (104). The 384-well plate was blocked using PBS + 1% BSA as described earlier, followed by a GVB++ wash (Complement Technology, B100). HIVIG (NIH HIV Reagent Program, ARP-3957), bnAb 10-1074 IgG1 [heavy and light chains were cloned in pCMV vector, and the antibody was expressed in HEK Expi cells (Gibco, A14635) following the manufacturer's instruction], bnAb VRC01 IgG1 [heavy and light chain plasmids for antibody expression (NIH AIDS Reagent Program, ARP-12035 and ARP-12036) were used to express the antibody in HEK Expi cells (Gibco, A14635)], or buffer alone was added to microspheres coupled with each HIV-envelope protein, diluted in assay buffer to 60 beads/well of each antigen, and incubated with shaking for 2 hours at room temperature. The final concentration of antibodies was 15 $\mu\text{g}/\text{mL}$. All the dilutions were performed in ice-cold GVB++. Following antibody binding, the plate was washed on a plate washer using PBS + 0.1% Tween 20, and the complement deposition activity of sera at 1:400 and 1:40,000 for C1q deposition and 1:40 and 1:400 for C3b deposition was assayed following incubation at 37°C for 30 min. The plate was washed using PBS plus 0.1% Tween 20 using an automatic plate washer. For detection of C1q, 37 μL of 1:100 dilution of biotin-anti-human-C1q (Quidel, A700) was added. The antibody and beads were mixed by sonication and vortexing to reduce bead clumping. The plate was sealed and wrapped and then allowed to incubate for 1 hour at room temperature with agitation at 1,000 rpm. Post washing, 37 μL of 1:500 SA-PE (Agilent Technologies, PJ315-1) was added as a detection agent. The plate was sonicated and vortexed and then allowed to incubate at room temperature, at 1,000 rpm for 1 hour. For C3b detection, 1:300 dilution of ms-anti-human-C3b (Cedarlane Labs, CL7636AP) was added as primary antibody, while goat anti-ms-IgG-PE, human adsorbed (Southern Biotech, 1010-09), was added as detection reagent. The plate was washed as using PBS + 0.1% Tween 20 using an automatic plate washer. The beads were suspended in 50 μL of sheath fluid, and data were acquired as described above.

The degree of antibody opsonization of beads was determined by detection of antibody binding with 40 μL of 0.65 $\mu\text{g}/\text{mL}$ of goat anti-human IgG antibody conjugated with PE (Southern Biotech, 2040-09), followed by washing and data acquisition as described above.

Sheep RBC hemolysis assay

The RBC hemolysis assay protocol was adapted from protocol published by Costabile et al. (105). A volume of 1.0 mL GVB++ (Complement Technology, B100) was added to 0.5-mL 100% packed sheep RBCs (Innovative Research, ISHRBC100P15ML) and mixed by inversion, followed by centrifugation at $600 \times g$ for 5 min. Supernatant was discarded, and this process was repeated two more times. After the final wash, cells were centrifuged at $900 \times g$ for 5 min to pack them, decanted, and resuspended in 4.5-mL

GVB++ to make a 10% solution of sheep RBCs. To this solution, an equal amount of 1:50 diluted hemolysin (rabbit anti-sheep erythrocyte antiserum) (Complement Technology, Hemolysin) was added drop wise while swirling the tube. The tube was incubated at 30°C for 30 min with a brief swirl at 15 min. Hemolysin-sensitized RBCs were stored at 4°C until the assay was performed. The assay was performed within 24 hours of sensitizing the RBCs.

A volume of 50 μ L of treated sheep RBCs was added to a V-bottom 96-well plate (USA Scientific, 18339600). To this, 50 μ L of 1:100 diluted serum was added. As a control to define total lysis, 50 μ L of distilled water was mixed with 50- μ L treated RBC, and as a no-lysis control, 50- μ L GVB++ was added to 50- μ L treated sheep RBCs. Heat-inactivated serum samples from pooled human and rhesus serum were used as additional negative controls. Heat inactivation was performed by heating serum at 58°C for 30 min. The plate was incubated at 37°C in a 5% CO₂ incubator for 30 min. Following centrifugation at 1,500 \times *g* for 5 min, 50 μ L from each well was transferred into a 96-well white clear-bottom polystyrene plate (Costar, 3610) and diluted with 50 μ L of water. Absorbance was measured at 540 nm using SpectraMax Paradigm Plate reader (Molecular Devices). Mean lysis across triplicates was calculated using the following formula: percentage lysis = $[\text{OD}_{540}(\text{test}) - \text{OD}_{540}(\text{blank})] / [\text{OD}_{540}(\text{total lysis}) - \text{OD}_{540}(\text{blank})] \times 100$. Data were collected for biological triplicates, and the average percentage lysis was reported.

Rituximab-induced complement-mediated lysis of Ramos cells

Ramos cells were washed with GVB++ (Complement Technology, B100) and seeded at 1×10^5 cells per well in a 96-well white clear-bottom polystyrene plate (Costar, 3610), to which 50 μ L of 10 μ g/mL of rituximab (AbMole Bioscience, M5219), rhesusized rituximab (NHPRR, 2B8R1), or GVB++ was added. The plate was subjected to orbital shaking at 200 rpm for 2 min. Following antibody binding, 50 μ L of a 1:100 dilution of serum was added. After repeating the shaking procedure, the plate was incubated at 37°C in a 5% CO₂ incubator for 1 hour and iced for 10 min, and then, 50 μ L of CytoTox-Glo Cytotoxicity assay reagent (Promega, G9291) was added. The plate was shaken at 900 rpm for 1 min on an orbital shaker and then incubated for 15 min at room temperature. Luminescence dependent on serum complement was measured using SpectraMax Paradigm Plate reader, and total luminescence was measured following addition of 50 μ L of lysis reagent and incubation at room temperature for 15 min. Relative antibody-dependent lytic activity was calculated as the ratio of luminescence of antibody-dependent complement-mediated cell death to luminescence observed for the no-antibody control condition. Mean values of assay duplicates were reported.

Effect of engineered antibodies on ADCML

Antibody-dependent complement-mediated lysis of Raji cells transduced with a retroviral vector encoding HIV-1_{YU-2b} Env was assessed as described previously (63). ADCML was assessed for bnAbs 10-1074 IgG1 (heavy and light chains were cloned in pCMV vector), 10e8v4 IgG1 (heavy and light chains were cloned in pCMV vector), and VRC01 IgG1 [heavy and light chain plasmids for antibody expression (NIH AIDS Reagent Program, ARP-12035 and ARP-12036)]. Mutations in the wild-type heavy-chain plasmid were performed using site-directed mutagenesis (Agilent, 200524) following the manufacturer's protocol to generate EG, KA, and EFTAE mutants (64–68). Antibodies were expressed in HEK Expi cells (Gibco, A14635) following the manufacturer's instruction.

For the ADCML assay, Raji cells expressing variable levels of surface Env were used (D2 clone and D4 clone) (63). Cells were mixed with 50% serum and 15 μ g/mL IgG and incubated for 24 hours at 37°C. Complement-mediated lysis was measured by staining with live/dead fixable aqua dead cell marker (Life Technologies, catalog no. L34957) prior to fixation. Flow cytometric analysis (Invitrogen, Attune NxT) of the fixed and stained cells was performed. Complement-dependent cytotoxicity (CDC) was calculated using the following formula: percentage lysis = [% of dead cells with antibody – % of dead cells

without antibody]/[100% of dead cells without antibody] × 100. Negative values were set to zero.

Complement-aided antibody-dependent phagocytosis

To gain insight into sex/species differences in complement activity, the aggregate opsonophagocytic activity of antibody-coated, complement-fixed particles was assessed by performing an antibody-dependent cellular phagocytosis assay (106) modified to include incubation with complement active serum. C'ADCP was tested with VRC01, 10-1074, and HIVIG antibodies. Antigen beads were prepared by conjugating 50- μ g HIV envelope protein gp140 SF162 (NIH HIV Reagent Program, ARP-12026) to a 400- μ L volume of fluorescent beads (1.7- to 2.2- μ m SPHERO Carboxyl Fluorescent Particles, Spherotech, Inc., CFP-2052-2) using carbodiimide chemistry as described previously (107). Serum samples were rapidly thawed, placed on ice, and subsequently distributed to 384-well plates (Greiner bio-one, 781906). The serum samples were diluted 1:72 in GVB++, and 50 μ L of diluted serum was added to a 96-well V-bottom plate (Plateone, 1833-9600).

Microspheres (1×10^8) were incubated with 15 μ g/mL of antibody [diluted in GVB++ (Complement Technology, B100)] for 2 hours at 4°C with end-over-end mixing. Following the incubation, the microspheres were washed once, resuspended, and added to the V-bottom plates on ice (final serum concentration = 1:144). Plates were incubated at 37°C (orbital shaking, 800 rpm) for 30 min and then placed on ice to stop the reaction before centrifugation at $4,000 \times g$ for 5 min. After decanting, beads were resuspended in 100 μ L of RPMI 1640 + 10% FBS and finally transferred to flat-bottom 96-well tissue-culture plates (Costar, 09-761-145), to which 100 μ L of THP-1 cells (viability >90%) at a concentration of 1×10^5 cells/mL was added to each well, resulting in a final effector (THP-1 cells) to target (bead coated with antibody and fixed with complement) ratio of 1:5. The effectors and target were allowed to be incubated at 37°C overnight prior to fixation with 4% paraformaldehyde. The number of beads phagocytosed was measured by flow cytometer on a MACSQuant (Miltenyi Biotec) instrument. Phagocytosis score was derived as an integrated MFI by multiplying the percentage of fluorescent (bead positive) THP-1 cells by the median fluorescent intensity of positive cells.

Data analysis

Data were analyzed and graphed using Graph Pad Prism (version 9.4.1), Rstudio (version 4.2.1), and FloJo (BD Biosciences). Packages ggplot2 (108), tidyverse (109), dplyr (110), and ggpubr (111) were used to analyze data and generate some of the graphs.

ACKNOWLEDGMENTS

HIVIG was obtained through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: Polyclonal Anti-Human Immunodeficiency Virus Immune Globulin, Pooled Inactivated Human Sera, ARP-3957, and contributed by the NABI and National Heart Lung and Blood Institute (Dr. Luiz Barbosa). VRC01 heavy and light chain in expression vector plasmids (ARP-12035,12036) were also obtained through the NIH HIV reagent program and contributed by Josh Mascola. Some of the HIV-1 gp140 antigens produced in CHO cells lines (ARP-12063, 12064, 12065, 12066) were obtained from the NIH HIV reagent program, contributed by DAIDS/NIAID, and produced by Polymun Scientific, Inc. A few other HIV-1 gp140 antigens produced in HEK 293F cells (ARP-12572, 12573, 12575, 12577, 12581) were obtained from the NIH HIV reagent program and contributed by Dr. Barton F. Haynes and Hua-Xin Liao. HIV-1 gp140 protein for SF162 envelope ectodomain produced in HEK293T cells was obtained from the NIH HIV reagent program and contributed by Dr. Leo Stamatatos. Plasmid for production of HIV gp140 protein trimer from strain YU2 (ARP-12133) was obtained from the NIH HIV reagent program and contributed by Dr. Joseph Sodroski. The simianized anti-CD20 (Rh Rtx) (2B8R1) was obtained from the NIH Non-human Primate Reagent Resource (NHPRR).

These studies were supported in part by NIAID P01AI162242, R01AI129801, Institut Pasteur funds, Fondation pour la Recherche Médicale (FRM), ANRS-MIE, the Vaccine Research Institute (ANR-10-LABX-77), HERA European program (DURABLE consortium), Labex IBEID (ANR-10-LABX-62-IBEID), ANR, and ANR/FRM Flash Covid grants.

N.S.K., B.S.G., J.D., and T.B. collected the experimental data. A.J.H. selected and provided the rhesus macaque serum samples. O.S. and M.E.A. supervised the research. N.S.K. analyzed the data, prepared figures, and drafted the manuscript. N.S.K. and M.E.A. finalized the manuscript. All authors reviewed and edited the manuscript.

AUTHOR AFFILIATIONS

¹Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire, USA

²Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA

³Institut Pasteur, Université de Paris, CNRS UMR3569, Virus and Immunity Unit, Paris, France

⁴Vaccine Research Institute, Créteil, France

⁵Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, USA

PRESENT ADDRESS

Benjamin S. Goldberg, Metaphore Biotechnologies Inc., Cambridge, Massachusetts, USA

Jérémy Dufloo, Institute for Integrative Systems Biology (I2SysBio), Universitat da Valencia-CSIC, Valencia, Spain

AUTHOR ORCIDs

Natasha S. Kelkar  <http://orcid.org/0009-0007-2942-7488>

Jérémy Dufloo  <http://orcid.org/0000-0002-4963-1378>

Margaret E. Ackerman  <http://orcid.org/0000-0002-4253-3476>

FUNDING

Funder	Grant(s)	Author(s)
HHS NIH National Institute of Allergy and Infectious Diseases (NIAID)	P01AI162242, R01AI129801	Margaret E. Ackerman
Fondation pour la Recherche Médicale (FRM)		Olivier Schwartz
Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS)	MIE, ANR-10-LABX-77, ANR-10-LABX-62-IBEID, Flash Covid grants	Olivier Schwartz

ADDITIONAL FILES

The following material is available [online](#).

Supplemental Material

Data File S1 (mBio00282-24-s0001.xlsx). Level of complement proteins in human and rhesus sera.

Data File S2 (mBio00282-24-s0002.xlsx). Antibody-dependent deposition of complement protein C1q by human and rhesus serum.

Data File S3 (mBio00282-24-s0003.xlsx). Antibody-dependent deposition of complement protein C3b by human and rhesus serum.

Supplemental Material (mBio00282-24-s0004.pdf). Supplemental figures, tables, and legends.

REFERENCES

- Fish EN. 2008. The X-files in immunity: sex-based differences predispose immune responses. *Nat Rev Immunol* 8:737–744. <https://doi.org/10.1038/nri2394>
- Flanagan KL. 2014. Sexual dimorphism in biomedical research: a call to analyse by sex. *Trans R Soc Trop Med Hyg* 108:385–387. <https://doi.org/10.1093/trstmh/tru079>
- Klein SL, Flanagan KL. 2016. Sex differences in immune responses. *Nat Rev Immunol* 16:626–638. <https://doi.org/10.1038/nri.2016.90>
- Hill-Burns EM, Clark AG. 2009. X-linked variation in immune response in *Drosophila melanogaster*. *Genetics* 183:1477–1491. <https://doi.org/10.1534/genetics.108.093971>
- Taylor K, Kimbrell DA. 2007. Host immune response and differential survival of the sexes in *Drosophila*. *Fly (Austin)* 1:197–204. <https://doi.org/10.4161/fly.5082>
- Bienvenu LA, Noonan J, Wang X, Peter K. 2020. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. *Cardiovasc Res* 116:2197–2206. <https://doi.org/10.1093/cvr/cvaa284>
- Gersh FL, O'Keefe JH, Henry BM. 2021. COVID-19, the female immune advantage, and cardiovascular impact. *Mayo Clin Proc* 96:820–821. <https://doi.org/10.1016/j.mayocp.2020.12.021>
- Qi S, Ngwa C, Morales Scheihing DA, Al Mamun A, Ahnstedt HW, Finger CE, Colpo GD, Sharmeen R, Kim Y, Choi HA, McCullough LD, Liu F. 2021. Sex differences in the immune response to acute COVID-19 respiratory tract infection. *Biol Sex Differ* 12:66. <https://doi.org/10.1186/s13293-021-00410-2>
- Zhao G, Xu Y, Li J, Cui X, Tan X, Zhang H, Dang L. 2021. Sex differences in immune responses to SARS-CoV-2 in patients with COVID-19. *Biosci Rep* 41:BSR20202074. <https://doi.org/10.1042/BSR20202074>
- Gadi N, Wu SC, Spihlman AP, Moulton VR. 2020. What's sex got to do with COVID-19? gender-based differences in the host immune response to coronaviruses. *Front Immunol* 11:2147. <https://doi.org/10.3389/fimmu.2020.02147>
- Collazos J, Asensi V, Cartón JA. 2007. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. *AIDS* 21:835–843. <https://doi.org/10.1097/QAD.0b013e3280b0774a>
- Wang C, Lashua LP, Carter CE, Johnson SK, Wang M, Ross TM, Ghedin E, Zhang B, Forst CV. 2022. Sex disparities in influenza: a multiscale network analysis. *iScience* 25:104192. <https://doi.org/10.1016/j.isci.2022.104192>
- Riggenbach MM, Haralambieva IH, Ovsyannikova IG, Schaid DJ, Poland GA, Kennedy RB. 2022. Mumps virus-specific immune response outcomes and sex-based differences in a cohort of healthy adolescents. *Clin Immunol* 234:108912. <https://doi.org/10.1016/j.clim.2021.108912>
- Huang Z, Chen B, Liu X, Li H, Xie L, Gao Y, Duan R, Li Z, Zhang J, Zheng Y, Su W. 2021. Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis. *Proc Natl Acad Sci U S A* 118:e2023216118. <https://doi.org/10.1073/pnas.2023216118>
- Abdullah M, Chai P-S, Chong M-Y, Tohit ERM, Ramasamy R, Pei CP, Vidyadaran S. 2012. Gender effect on *in vitro* lymphocyte subset levels of healthy individuals. *Cell Immunol* 272:214–219. <https://doi.org/10.1016/j.cellimm.2011.10.009>
- Spitzer JA. 1999. Gender differences in some host defense mechanisms. *Lupus* 8:380–383. <https://doi.org/10.1177/096120339900800510>
- Uppal SS, Verma S, Dhot PS. 2003. Normal values of CD4 and CD8 lymphocyte subsets in healthy Indian adults and the effects of sex, age, ethnicity, and smoking. *Cytometry B Clin Cytom* 52:32–36. <https://doi.org/10.1002/cyto.b.10011>
- Lisse IM, Aaby P, Whittle H, Jensen H, Engelmann M, Christensen LB. 1997. T-lymphocyte subsets in West African children: impact of age, sex, and season. *J Pediatr* 130:77–85. [https://doi.org/10.1016/s0022-3476\(97\)70313-5](https://doi.org/10.1016/s0022-3476(97)70313-5)
- Lee BW, Yap HK, Chew FT, Quah TC, Prabhakaran K, Chan GS, Wong SC, Seah CC. 1996. Age- and sex-related changes in lymphocyte subpopulations of healthy Asian subjects: from birth to adulthood. *Cytometry* 26:8–15. [https://doi.org/10.1002/\(SICI\)1097-0320\(19960315\)26:1<8::AID-CYTO2>3.0.CO;2-E](https://doi.org/10.1002/(SICI)1097-0320(19960315)26:1<8::AID-CYTO2>3.0.CO;2-E)
- Amadori A, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli GA, Clementi M, Chieco-Bianchi L. 1995. Genetic control of the CD4/CD8 T-cell ratio in humans. *Nat Med* 1:1279–1283. <https://doi.org/10.1038/nm1295-1279>
- Wikby A, Månsson IA, Johansson B, Strindhall J, Nilsson SE. 2008. The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20–100 years of age. *Biogerontology* 9:299–308. <https://doi.org/10.1007/s10522-008-9138-6>
- Weinstein Y, Ran S, Segal S. 1984. Sex-associated differences in the regulation of immune responses controlled by the MHC of the mouse. *J Immunol* 132:656–661.
- Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. 2019. Sex differences in vaccine-induced humoral immunity. *Semin Immunopathol* 41:239–249. <https://doi.org/10.1007/s00281-018-0726-5>
- Klein SL, Jedlicka A, Pekosz A. 2010. The Xs and Y of immune responses to viral vaccines. *Lancet Infect Dis* 10:338–349. [https://doi.org/10.1016/S1473-3099\(10\)70049-9](https://doi.org/10.1016/S1473-3099(10)70049-9)
- Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. 2020. The prevalence of autoimmune disorders in women: a narrative review. *Cureus* 12:e8094. <https://doi.org/10.7759/cureus.8094>
- Jacobsen H, Klein SL. 2021. Sex differences in immunity to viral infections. *Front Immunol* 12:720952. <https://doi.org/10.3389/fimmu.2021.720952>
- Klein SL. 2000. The effects of hormones on sex differences in infection: from genes to behavior. *Neurosci Biobehav Rev* 24:627–638. [https://doi.org/10.1016/s0149-7634\(00\)00027-0](https://doi.org/10.1016/s0149-7634(00)00027-0)
- Oertelt-Prigione S. 2012. The influence of sex and gender on the immune response. *Autoimmun Rev* 11:A479–A485. <https://doi.org/10.1016/j.autrev.2011.11.022>
- Lu PY, Guerin DJ, Lin S, Chaudhury S, Ackerman ME, Bolton DL, Wallqvist A. 2021. Immunoprofiling correlates of protection against SHIV infection in adjuvanted HIV-1 pox-protein vaccinated rhesus macaques. *Front Immunol* 12:625030. <https://doi.org/10.3389/fimmu.2021.625030>
- Om K, Paquin-Proulx D, Montero M, Peachman K, Shen X, Wieczorek L, Beck Z, Weiner JA, Kim D, Li Y, et al. 2020. Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. *PLoS Pathog* 16:e1008764. <https://doi.org/10.1371/journal.ppat.1008764>
- Miller-Novak LK, Das J, Musich TA, Demberg T, Weiner JA, Venzon DJ, Mohanram V, Vargas-Inchaustegui DA, Tuero I, Ackerman ME, Alter G, Robert-Guroff M. 2018. Analysis of complement-mediated lysis of Simian immunodeficiency virus (SIV) and SIV-infected cells reveals sex differences in vaccine-induced immune responses in rhesus macaques. *J Virol* 92:e00721-18. <https://doi.org/10.1128/JVI.00721-18>
- Tuero I, Mohanram V, Musich T, Miller L, Vargas-Inchaustegui DA, Demberg T, Venzon D, Kalisz I, Kalyanaraman VS, Pal R, Ferrari MG, LaBranche C, Montefiori DC, Rao M, Vaccari M, Franchini G, Barnett SW, Robert-Guroff M. 2015. Mucosal B cells are associated with delayed SIV acquisition in vaccinated female but not male rhesus macaques following SIVmac251 rectal challenge. *PLoS Pathog* 11:e1005101. <https://doi.org/10.1371/journal.ppat.1005101>
- Vargas-Inchaustegui DA, Demers A, Shaw JM, Kang G, Ball D, Tuero I, Musich T, Mohanram V, Demberg T, Karpova TS, Li Q, Robert-Guroff M. 2016. Vaccine induction of lymph node-resident Simian immunodeficiency virus Env-specific T follicular helper cells in rhesus macaques. *J Immunol* 196:1700–1710. <https://doi.org/10.4049/jimmunol.1502137>
- Mohanram V, Demberg T, Musich T, Tuero I, Vargas-Inchaustegui DA, Miller-Novak L, Venzon D, Robert-Guroff M. 2016. B cell responses associated with vaccine-induced delayed SIVmac251 acquisition in female rhesus macaques. *J Immunol* 197:2316–2324. <https://doi.org/10.4049/jimmunol.1600544>
- Xia HJ, Zhang GH, Wang RR, Zheng YT. 2009. The influence of age and sex on the cell counts of peripheral blood leukocyte subpopulations in Chinese rhesus macaques. *Cell Mol Immunol* 6:433–440. <https://doi.org/10.1038/cmi.2009.55>
- Rowe JM, Wu MM, Fleming SD. 2020. Complement initiation and regulation differ by sex in intestinal ischemia reperfusion injury. *J Immunol* 204:79. <https://doi.org/10.4049/jimmunol.204.Supp.79.15>

37. Nilsson B, Nilsson Ekdahl K. 2012. The tick-over theory revisited: is C3 a contact-activated protein? *Immunobiology* 217:1106–1110. <https://doi.org/10.1016/j.imbio.2012.07.008>
38. Lachmann PJ, Lay E, Seilly DJ. 2018. Experimental confirmation of the C3 tickover hypothesis by studies with an Ab (S77) that inhibits tickover in whole serum. *FASEB J* 32:123–129. <https://doi.org/10.1096/fj.201700734>
39. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. 2015. Complement system part I - molecular mechanisms of activation and regulation. *Front Immunol* 6:262. <https://doi.org/10.3389/fimmu.2015.00262>
40. Pepys MB. 1972. Role of complement in induction of the allergic response. *Nat New Biol* 237:157–159. <https://doi.org/10.1038/newbio237157a0>
41. Dunkelberger JR, Song W-C. 2010. Complement and its role in innate and adaptive immune responses. *Cell Res* 20:34–50. <https://doi.org/10.1038/cr.2009.139>
42. Carroll MC. 2004. The complement system in B cell regulation. *Mol Immunol* 41:141–146. <https://doi.org/10.1016/j.molimm.2004.03.017>
43. Carroll MC. 2008. Complement and humoral immunity. *Vaccine* 26:128–33. <https://doi.org/10.1016/j.vaccine.2008.11.022>
44. Irvine DJ, Read BJ. 2020. Shaping humoral immunity to vaccines through antigen-displaying nanoparticles. *Curr Opin Immunol* 65:1–6. <https://doi.org/10.1016/j.coi.2020.01.007>
45. Tokatlian T, Read BJ, Jones CA, Kulp DW, Menis S, Chang JYH, Steichen JM, Kumari S, Allen JD, Dane EL, Liguori A, Sangesland M, Lingwood D, Crispin M, Schief WR, Irvine DJ. 2019. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. *Science* 363:649–654. <https://doi.org/10.1126/science.aat9120>
46. Kim AHJ, Dimitriou ID, Holland MCH, Mastellos D, Mueller YM, Altman JD, Lambris JD, Katsikis PD. 2004. Complement C5a receptor is essential for the optimal generation of antiviral CD8(+) T cell responses. *J Immunol* 173:2524–2529. <https://doi.org/10.4049/jimmunol.173.4.2524>
47. Zhang XH, Kimura Y, Fang CY, Zhou L, Sfyroera G, Lambris JD, Wetsel RA, Miwa T, Song WC. 2007. Regulation of toll-like receptor-mediated inflammatory response by complement *in vivo*. *Blood* 110:228–236. <https://doi.org/10.1182/blood-2006-12-063636>
48. Wagner C, Ochmann C, Schoels M, Giese T, Stegmaier S, Richter R, Hug F, Hänsch GM. 2006. The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes. *Mol Immunol* 43:643–651. <https://doi.org/10.1016/j.molimm.2005.04.006>
49. Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J, Spendlove I. 2006. Costimulation via CD55 on human CD4+ T cells mediated by CD97. *J Immunol* 177:1070–1077. <https://doi.org/10.4049/jimmunol.177.2.1070>
50. UniProt Consortium. 2021. UniProt: the universal protein knowledge-base in 2021. *Nucleic Acids Res* 49:D480–D489. <https://doi.org/10.1093/nar/gkaa1100>
51. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. *J Mol Biol* 215:403–410. [https://doi.org/10.1016/S0022-2836\(05\)80360-2](https://doi.org/10.1016/S0022-2836(05)80360-2)
52. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 22:4673–4680. <https://doi.org/10.1093/nar/22.22.4673>
53. Kojouharova MS, Gadjeva MG, Tsacheva IG, Zlatarova A, Roumenina LT, Tchoubadjeva MI, Atanasov BP, Waters P, Urban BC, Sim RB, Reid KBM, Kishore U. 2004. Mutational analyses of the recombinant globular regions of human C1q A, B, and C chains suggest an essential role for arginine and histidine residues in the C1q-IgG interaction. *J Immunol* 172:4351–4358. <https://doi.org/10.4049/jimmunol.172.7.4351>
54. Zlatarova AS, Rouseva M, Roumenina LT, Gadjeva M, Kolev M, Dobrev I, Olova N, Ghai R, Jensenius JC, Reid KBM, Kishore U, Kojouharova MS. 2006. Existence of different but overlapping IgG- and IgM-binding sites on the globular domain of human C1q. *Biochemistry* 45:9979–9988. <https://doi.org/10.1021/bi060539v>
55. Gadjeva MG, Rouseva MM, Zlatarova AS, Reid KBM, Kishore U, Kojouharova MS. 2008. Interaction of human C1q with IgG and IgM: revisited. *Biochemistry* 47:13093–13102. <https://doi.org/10.1021/bi801131h>
56. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PNP, Spencer DIR, Seaman MS, Schuitemaker H, Feizi T, Nussenzweig MC, Bjorkman PJ. 2012. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. *Proc Natl Acad Sci U S A* 109:E3268–E3277. <https://doi.org/10.1073/pnas.1217207109>
57. Wu X, Yang Z-Y, Li Y, Hogerkerp C-M, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. *Science* 329:856–861. <https://doi.org/10.1126/science.1187659>
58. Ross GD. 1986. Introduction and history of complement research. In *Immunobiology of the complement system*
59. Chabannes M, Bordereau P, Martins PV, Dragon-Durey MA. 2021. Sheep erythrocyte preparation for hemolytic tests exploring complement functional activities. *Methods Mol Biol* 2227:61–67. https://doi.org/10.1007/978-1-0716-1016-9_6
60. Kwon YD, Georgiev IS, Ofek G, Zhang B, Asokan M, Bailer RT, Bao A, Caruso W, Chen X, Choe M, et al. 2016. Optimization of the solubility of HIV-1-neutralizing antibody 10E8 through somatic variation and structure-based design. *J Virol* 90:5899–5914. <https://doi.org/10.1128/JVI.03246-15>
61. Goldberg BS, Spencer DA, Pandey S, Ordonez T, Barnette P, Yu Y, Gao L, Dufloo J, Bruel T, Schwartz O, Ackerman ME, Hessel AJ. 2023. Complement contributes to antibody-mediated protection against repeated SHIV challenge. *Proc Natl Acad Sci U S A* 120:e2221247120. <https://doi.org/10.1073/pnas.2221247120>
62. Spencer DA, Goldberg BS, Pandey S, Ordonez T, Dufloo J, Barnette P, Sutton WF, Henderson H, Agnor R, Gao L, Bruel T, Schwartz O, Haigwood NL, Ackerman ME, Hessel AJ. 2022. Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis. *Nat Commun* 13:662. <https://doi.org/10.1038/s41467-022-28250-7>
63. Dufloo J, Guivel-Benhassine F, Buchrieser J, Lorin V, Grzelak L, Dupouy E, Mestrallet G, Bourdic K, Lambotte O, Mouquet H, Bruel T, Schwartz O. 2020. Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells. *EMBO Rep* 21:e49351. <https://doi.org/10.15252/embr.201949351>
64. Hessel AJ, Hangartner L, Hunter M, Havenith CEG, Beurskens FJ, Bakker JM, Lanigan CMS, Landucci G, Forthal DN, Parren P, Marx PA, Burton DR. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. *Nature* 449:101–104. <https://doi.org/10.1038/nature06106>
65. Moore GL, Chen H, Karki S, Lazar GA. 2010. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. *MAbs* 2:181–189. <https://doi.org/10.4161/mabs.2.2.11158>
66. Wirt T, Roskopf S, Rösner T, Eichholz KM, Kahrs A, Lutz S, Kretschmer A, Valerius T, Klausz K, Otte A, Gramatzki M, Peipp M, Kellner C. 2017. An Fc double-engineered CD20 antibody with enhanced ability to trigger complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. *Transfus Med Hemother* 44:292–300. <https://doi.org/10.1159/000479978>
67. Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJR, van de Winkel JGJ, Wilson IA, Koster AJ, Taylor RP, Saphire EO, Burton DR, Schuurman J, Gros P, Parren PW. 2014. Complement is activated by IgG hexamers assembled at the cell surface. *Science* 343:1260–1263. <https://doi.org/10.1126/science.1248943>
68. Goldberg BS, Ackerman ME. 2020. Antibody-mediated complement activation in pathology and protection. *Immunol Cell Biol* 98:305–317. <https://doi.org/10.1111/imcb.12324>
69. Xu D, Alegre M-L, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren P, Bluestone JA, Jolliffe LK, Zivin RA. 2000. *In vitro* characterization of five humanized OKT3 effector function variant antibodies. *Cell Immunol* 200:16–26. <https://doi.org/10.1006/cimm.2000.1617>
70. Hezareh M, Hessel AJ, Jensen RC, van de Winkel JG, Parren PW. 2001. Effector function activities of a panel of mutants of a broadly

- neutralizing antibody against human immunodeficiency virus type 1. *J Virol* 75:12161–12168. <https://doi.org/10.1128/JVI.75.24.12161-12168.2001>
71. Tohyama Y, Yamamura H. 2006. Complement-mediated phagocytosis—the role of Syk. *IUBMB Life* 58:304–308. <https://doi.org/10.1080/15216540600746377>
 72. Vidarsson G, van de Winkel JG. 1998. Fc receptor and complement receptor-mediated phagocytosis in host defence. *Curr Opin Infect Dis* 11:271–278. <https://doi.org/10.1097/00001432-199806000-00002>
 73. Aderem A, Underhill DM. 1999. Mechanisms of phagocytosis in macrophages. *Annu Rev Immunol* 17:593–623. <https://doi.org/10.1146/annurev.immunol.17.1.593>
 74. Gaya da Costa M, Poppelaars F, van Kooten C, Mollnes TE, Tedesco F, Würzner R, Trouw LA, Truedsson L, Daha MR, Roos A, Seelen MA. 2018. Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population. *Front Immunol* 9:2664. <https://doi.org/10.3389/fimmu.2018.02664>
 75. Wu MM, Rowe JM, Fleming SD. 2021. Complement initiation varies by sex in intestinal ischemia reperfusion injury. *Front Immunol* 12:649882. <https://doi.org/10.3389/fimmu.2021.649882>
 76. Fan JD, Wagner BL, McDonnell DP. 1996. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. *Mol Endocrinol* 10:1605–1616. <https://doi.org/10.1210/mend.10.12.8961270>
 77. Kumwenda P, Cottier F, Hendry AC, Kneafsey D, Keevan B, Gallagher H, Tsai HJ, Hall RA. 2022. Estrogen promotes innate immune evasion of *Candida albicans* through inactivation of the alternative complement system. *Cell Rep* 38:110183. <https://doi.org/10.1016/j.celrep.2021.110183>
 78. Chen X, Gula H, Pius T, Ou C, Gomozkova M, Wang LX, Schneewind O, Missiakas D. 2023. Immunoglobulin G subclasses confer protection against *Staphylococcus aureus* bloodstream dissemination through distinct mechanisms in mouse models. *Proc Natl Acad Sci U S A* 120:e2220765120. <https://doi.org/10.1073/pnas.2220765120>
 79. Boesch AW, Osei-Owusu NY, Crowley AR, Chu TH, Chan YN, Weiner JA, Bharadwaj P, Hards R, Adamo ME, Gerber SA, Cocklin SL, Schmitz JE, Miles AR, Eckman JW, Belli AJ, Reimann KA, Ackerman ME. 2016. Biophysical and functional characterization of rhesus macaque IgG subclasses. *Front Immunol* 7:589. <https://doi.org/10.3389/fimmu.2016.00589>
 80. Chan YN, Boesch AW, Osei-Owusu NY, Emileh A, Crowley AR, Cocklin SL, Finstad SL, Linde CH, Howell RA, Zentner I, Cocklin S, Miles AR, Eckman JW, Alter G, Schmitz JE, Ackerman ME. 2016. IgG binding characteristics of rhesus macaque FcγR. *J Immunol* 197:2936–2947. <https://doi.org/10.4049/jimmunol.1502252>
 81. Warncke M, Calzascia T, Coulot M, Balke N, Touil R, Kolbinger F, Heusser C. 2012. Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. *J Immunol* 188:4405–4411. <https://doi.org/10.4049/jimmunol.1200090>
 82. Grunst MW, Grandea AG, Janaka SK, Hammad I, Grimes P, Karl JA, Wiseman R, O'Connor DH, Evans DT. 2020. Functional interactions of common allotypes of rhesus macaque FcγR2A and FcγR3A with human and macaque IgG subclasses. *J Immunol* 205:3319–3332. <https://doi.org/10.4049/jimmunol.2000501>
 83. Boesch AW, Miles AR, Chan YN, Osei-Owusu NY, Ackerman ME. 2017. IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs. *MAbs* 9:455–465. <https://doi.org/10.1080/19420862.2016.1274845>
 84. Richardson SI, Lambson BE, Crowley AR, Bashirova A, Scheepers C, Garrett N, Abdool Karim S, Mkhize NN, Carrington M, Ackerman ME, Moore PL, Morris L. 2019. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. *PLoS Pathog* 15:e1008064. <https://doi.org/10.1371/journal.ppat.1008064>
 85. Crowley AR, Richardson SI, Tuyishime M, Jennewein M, Bailey MJ, Lee J, Alter G, Ferrari G, Morris L, Ackerman ME. 2023. Functional consequences of allotypic polymorphisms in human immunoglobulin G subclasses. *Immunogenetics* 75:1–16. <https://doi.org/10.1007/s00251-022-01272-7>
 86. Chu TH, Patz EF, Ackerman ME. 2021. Coming together at the hinges: therapeutic prospects of IgG3. *MAbs* 13:1882028. <https://doi.org/10.1080/19420862.2021.1882028>
 87. Wen L, Atkinson JP, Giclas PC. 2004. Clinical and laboratory evaluation of complement deficiency. *J Allergy Clin Immunol* 113:585–593. <https://doi.org/10.1016/j.jaci.2004.02.003>
 88. Steinsson K, Erlendsson K, Valdimarsson H. 1989. Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months. *Arthritis Rheum* 32:906–913.
 89. Bork K, Meng G, Staubach P, Hardt J. 2006. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. *Am J Med* 119:267–274. <https://doi.org/10.1016/j.amjmed.2005.09.064>
 90. Agostoni A, Cicardi M. 1992. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. *Medicine (Baltimore)* 71:206–215. <https://doi.org/10.1097/00005792-199207000-00003>
 91. Bouillet L, Launay D, Fain O, Boccon-Gibod I, Laurent J, Martin L, Montauban V, Finck K, Bouée S, Gompel A, Kanny G, French National Reference Center for Hereditary Angioedema (CREAK). 2013. Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. *Ann Allergy Asthma Immunol* 111:290–294. <https://doi.org/10.1016/j.anaai.2013.07.012>
 92. Banerji A, Riedl M. 2016. Managing the female patient with hereditary angioedema. *Womens Health (Lond)* 12:351–361. <https://doi.org/10.2217/whe.16.6>
 93. Sodhi EU, Philpott HT, Carter MM, Birmingham TB, Appleton CT. 2022. Sex-differences and associations between complement activation and synovial vascularization in patients with late-stage knee osteoarthritis. *Front Immunol* 13:890094. <https://doi.org/10.3389/fimmu.2022.890094>
 94. Carroll MV, Sim RB. 2011. Complement in health and disease. *Adv Drug Deliv Rev* 63:965–975. <https://doi.org/10.1016/j.addr.2011.06.005>
 95. Mollnes TE, Fosse E. 1994. The complement system in trauma-related and ischemic tissue damage: a brief review. *Shock* 2:301–310. <https://doi.org/10.1097/00024382-199410000-00012>
 96. Neher MD, Weckbach S, Flierl MA, Huber-Lang MS, Stahel PF. 2011. Molecular mechanisms of inflammation and tissue injury after major trauma—is complement the “bad guy”? *J Biomed Sci* 18:90. <https://doi.org/10.1186/1423-0127-18-90>
 97. Sewell DL, Nacewicz B, Liu F, Macvilay S, Erdei A, Lambris JD, Sandor M, Fabry Z. 2004. Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. *J Neuroimmunol* 155:55–63. <https://doi.org/10.1016/j.jneuroim.2004.06.003>
 98. Kaczorowski SL, Schiding JK, Toth CA, Kochanek PM. 1995. Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. *J Cereb Blood Flow Metab* 15:860–864. <https://doi.org/10.1038/jcbfm.1995.107>
 99. Leinase I, Schmidt OI, Thurman JM, Hossini AM, Rozanski M, Taha ME, Scheffler A, John T, Smith WR, Holers VM, Stahel PF. 2006. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. *Exp Neurol* 199:454–464. <https://doi.org/10.1016/j.expneurol.2006.01.033>
 100. Leinase I, Rozanski M, Harhausen D, Thurman JM, Schmidt OI, Hossini AM, Taha ME, Rittirsch D, Ward PA, Holers VM, Ertel W, Stahel PF. 2007. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. *J Neuroinflammation* 4:13. <https://doi.org/10.1186/1742-2094-4-13>
 101. Kotimaa J, Klar-Mohammad N, Gueler F, Schilders G, Jansen A, Rutjes H, Daha MR, van Kooten C. 2016. Sex matters: systemic complement activity of female C57BL/6J and BALB/cJ mice is limited by serum terminal pathway components. *Mol Immunol* 76:13–21. <https://doi.org/10.1016/j.molimm.2016.06.004>
 102. Marin AI, Poppelaars F, Wagner BD, Palestine AG, Patnaik JL, Holers VM, Frazer-Abel AA, Mathias MT, Manoharan N, Fonteh CN, Mandava N, Lynch AM, Grp U. 2022. Sex and age-related differences in complement factors among patients with intermediate age-related macular degeneration. *Transl Vis Sci Technol* 11:22. <https://doi.org/10.1167/tvst.11.5.22>

103. Tang H, Panemangalore R, Yarde M, Zhang L, Cvijic ME. 2016. 384-well multiplexed luminex cytokine assays for lead optimization. *SLAS Discovery* 21:548–555. <https://doi.org/10.1177/1087057116644164>
104. Brown EP, Dowell KG, Boesch AW, Normandin E, Mahan AE, Chu T, Barouch DH, Bailey-Kellogg C, Alter G, Ackerman ME. 2017. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. *J Immunol Methods* 443:33–44. <https://doi.org/10.1016/j.jim.2017.01.010>
105. Costabile M. 2010. Measuring the 50% haemolytic complement (CH50) activity of serum. *J Vis Exp* 37:1923. <https://doi.org/10.3791/1923>
106. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, Irvine DJ, Burton DR, Alter G. 2011. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. *J Immunol Methods* 366:8–19. <https://doi.org/10.1016/j.jim.2010.12.016>
107. Chu TH, Crowley AR, Backes I, Chang C, Tay M, Broge T, Tuyishime M, Ferrari G, Seaman MS, Richardson SI, Tomaras GD, Alter G, Leib D, Ackerman ME. 2020. Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. *PLoS Pathog* 16:e1008083. <https://doi.org/10.1371/journal.ppat.1008083>
108. Wickham H. 2016. *Ggplot2: elegant graphics for data analysis*. Springer-Verlag New York, Cham.
109. Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Pedersen T, Miller E, Bache S, Müller K, Ooms J, Robinson D, Seidel D, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H. 2019. Welcome to the tidyverse. *J Open Source Softw* 4:1686. <https://doi.org/10.21105/joss.01686>
110. Wickham H, François R, Henry L, Müller K, Vaughan D. 2023. *Dplyr: a grammar of data manipulation*. R package version 1.1.2. Available from: <https://CRAN.R-project.org/package=dplyr>
111. Kassambara A. 2023. *_ggpubr: 'ggplot2' based publication ready plots_*. R package version 0.6.0